Thread Content
【Market Analysis on China Pharmaceutical Network】Recently, the WeChat account of China Pharmaceutical Network (zyzhan_2012) published an article titled \"In the second half of 2018, pharmaceutical companies will face 9 major changes,\" which attracted readers’ attention. Although the first half of the year has not yet ended, some changes in the pharmaceutical industry indeed present both opportunities and challenges for those working in this field. The profound changes facing pharmaceutical companies also affect pharmaceutical equipment manufacturers to some extent, such as \"half of the pharmaceutical distributors disappearing\" and \"talent from foreign pharmaceutical companies moving to domestic firms\"; of course, in addition to these, pharmaceutical equipment manufacturers also face other changes. http://5b0988e595225.cdn.sohucs.com/images/20180511/59a4730f5863429eb1241ec55c55415b.jpeg (Images of pharmaceutical equipment sourced from China Pharmaceutical Network) Half of the drug distributors will disappear; a battle for survival among pharmaceutical equipment manufacturers is underway. 2018 was the year when the two-invoice system was fully implemented, and experts predict that half of the drug distributors will cease to exist by that year. Although such predictions are inevitably disheartening, most in the industry believe that as market demand in the pharmaceutical sector grows, particularly for high-quality products, and as pharmaceutical policies become stricter, more manufacturing companies will end up shutting down. The above analysis represents undoubtedly a major change for pharmaceutical equipment manufacturers, as the decrease in the number of drug suppliers means a reduction in the demand for pharmaceutical equipment, which in turn implies that the industry will see a significant increase in concentration under these circumstances. Some manufacturers say that the traditional production methods are becoming less effective; the landscape of the industry has changed, and the elimination of pharmaceutical equipment companies is imminent. Talents from foreign pharmaceutical companies are moving to local firms, and the trend toward more advanced pharmaceutical equipment is inevitable. Recently, Wu Xiaobin’s departure from Pfizer to join BeiGene, and Chao Shoubai’s move from AstraZeneca to Kangxinnuo, have become topics of discussion in the industry. Experts say that it is an emerging trend for talent from foreign pharmaceutical companies to move to local enterprises; this will not only enhance the core competitiveness of these local companies but also push the development of high-end domestic pharmaceutical products to new heights. Among them, pharmaceutical companies will also have increasingly higher demands for high-end pharmaceutical equipment. The demands for high-end pharmaceutical equipment encompass various factors, such as the most fundamental requirement of quality, energy conservation and environmental protection in line with policies and industry trends as well as intelligence, along with innovative technologies that are frequently mentioned. Overall, high-end equipment will place pharmaceutical equipment manufacturers in a situation marked by both opportunities and challenges, and this situation will become increasingly apparent as talent from foreign pharmaceutical companies leaves the sector. Major reforms in the traditional Chinese medicine industry: new requirements for pharmaceutical equipment. On May 10, the **Drug Administration issued the ‘Notice on 7 batches of drugs that do not meet the specified standards (No. 22, 2018)’. According to the announcement, the relevant authorities will take control measures such as sealing up and seizing products that do not meet the regulations, and require companies to suspend their sales and use of such products, recall them, and make necessary corrections. Since April, various regions across the country have issued announcements regarding substandard traditional Chinese medicine ingredients, indicating that a major overhaul of the traditional Chinese medicine industry is underway! The problems within this industry have long acted as a major obstacle to its development; these issues include not only problems with product quality but also problems related to market order and the manufacturing practices of traditional Chinese medicine companies. With the increased efforts from **and local authorities, traditional Chinese medicine companies will also carry out comprehensive reforms, including those related to pharmaceutical equipment. In response to this, comprehensive reforms will, on the one hand, set new requirements for pharmaceutical equipment manufacturers, while on the other hand, equipment products that do not meet these requirements will be phased out. Medical policies are being introduced frequently, with more changes awaiting response from pharmaceutical equipment manufacturers. Last year, medical experts said that this year would also be a year of many medical policies; as can be seen from articles such as \"March’s Major Medical Events: Reflecting the Current Situation and Indicating Industry Trends\" and \"April’s Major Medical Events: Policies to Guide Industry Development and Solve Practical Problems\" compiled by the author, there continues to be a trend of frequent introduction of medical policies. At this pace, many policies will be introduced in the second half of the year, and pharmaceutical equipment manufacturers will reap more benefits while facing greater challenges. However, although pharmaceutical equipment manufacturers saw the changes brought about by pharmaceutical policies last year – such as a series of environmental regulations that caught them off guard – the policies that have been announced so far suggest that there will be even more changes for these manufacturers to deal with. In the second half of the year, staying on high alert will become the norm for pharmaceutical equipment manufacturers. China has strong potential for new drug development, and competition among pharmaceutical equipment manufacturers has reached new levels. The value brought about by the successful development of new drugs is self-evident, but it also leads to greater competition among pharmaceutical equipment companies. The author has learned that the pace of new drug development in our country is accelerating, and with the implementation of a zero-tariff policy for anti-cancer drugs, new drug development is set to enter a new phase, while competition among pharmaceutical equipment manufacturers will also reach new heights. For pharmaceutical equipment manufacturers, integrating pharmaceutical processes with technology R&D equipment is both a challenge and an important factor for success in competition. At present, China’s pharmaceutical equipment manufacturers still have significant shortcomings when it comes to innovating equipment tailored to pharmaceutical manufacturing processes; however, the accelerating pace of new drug development may force these manufacturers to develop equipment that better suits such processes. Conclusion: The pharmaceutical industry is constantly undergoing changes, large or small, which bring both opportunities and challenges to manufacturers of pharmaceutical equipment. Change is not scary; what’s scary is that pharmaceutical equipment companies fail to notice it and take no action in response. There is a view in the industry: “Everyone is being changed by policies and the market; it’s terrifying to be involved without even realizing it.” ”For this article, the author has analyzed the changes that will occur in the industry in the second half of 2018 by taking into account the current situation. It’s still unknown what changes will occur in the future, but one thing remains constant: as long as companies follow a solid development path and proceed steadily, they should be able to cope successfully.